Guggenheim Maintains Buy on Praxis Precision Medicine, Raises Price Target to $1050
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $800 to $1050.
Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $800 to $1050.
